NeuroFrontiers

Researchers from the National Institutes of Health (NIH) found that 100 percent of the participants in this study had fatigue and experienced cognitive difficulties. So what can we learn from this new research to help us diagnose and treat patients with disabling neurological symptoms after they had COVID-19? To discuss the findings, Dr. Charles Turck is joined by Dr. Avindra Nath, Clinical Director of the National Institute of Neurological Disorders and Stroke.

Limb-girdle dystrophy (LGMD) is a group of inherited neuromuscular diseases with at least 34 variants, all affecting muscles of the limb-girdle region. Because LGMD is so variable, it can be hard to detect and there are no FDA-approved treatments currently. Advances in gene transfer therapy have been slow to emerge. However, helping clinicians detect LGMD and know the next best steps is critical to effective management of LGMD, along with identifying patients for clinical trials.

Duchenne Muscular Dystrophy, or DMD, is considered a rare disease, affecting 1 in 3,500 boy births. But to the patients afflicted-and to the families who love them-it is a painful, everyday experience. Current advances in gene transfer therapy are exciting. Helping clinicians interpret and utilize the outcomes of gene therapy clinical trials is critical to effective treatment and management of DMD, as is the coordination of multidisciplinary teams for the ongoing care of these patients.

Due to their clinical overlap, distinguishing between neurocognitive and psychiatric disorders can be challenging, but an accurate diagnosis is crucial for timely assessment and treatment. Find out how we can better identify and treat complex neurocognitive disorders such as Alzheimer's disease and other forms of dementia with Dr. Charles Turck and Dr. Lokesh Shahani, Associate Professor of Psychiatry and Behavioral Sciences at UT Health Houston McGovern Medical School who presented on this exact topic at the 2023 APA Annual Meeting.

Behavioral and psychological symptoms of dementia (BPSD) refers to a group of noncognitive symptoms that commonly occur in patients with dementia. While data shows efficacy for treatment modalities for these symptoms and behaviors, the use of psychotropic medications has been met with controversy due to their adverse effects. Tune in to hear Dr. Rajesh Tampi, Professor and Chairman of the Department of Psychiatry at Creighton School of Medicine, discuss how we can address those controversies while providing optimal care for our patients, which was the focus of his presentation at the 2023 American Psychiatric Association Annual Meeting.

Glioblastoma is the most common type of brain tumor while also being one of the most aggressive cancers in adults. So what do we need to know about ferroptosis? Dive in with Dr. Andrew Wilner as he’s joined by Dr. Dominique Higgins, Assistant Professor of Neurosurgery at the University of North Carolina School of Medicine.

Here to share some of the key presentations at the 2023 American Psychiatric Association (APA) Annual Meeting is Dr. Raj Tampi, Professor and Chairman of the Department of Psychiatry at Creighton School of Medicine.

Find out what previous and ongoing clinical trials are telling us about the use of cannabinoids to treat behavioral and psychological symptoms of dementia (BPSD) with Dr. Jerome Lisk and Dr. Raj Tampi, Professor and Chairman of the Department of Psychiatry at Creighton School of Medicine.

Changing the Conversation About Mental Health: Patient & Provider Perspectives is a series of conversations that explores the need to openly and honestly discuss mental health topics to help bridge the communications gap that can exist between health care providers and people with mental health disorders. Throughout this podcast, a clinician and a person with MDD engage in a conversation about a different aspect of MDD – from the journey to diagnosis to the impact of MDD.

The information in this podcast is not intended to serve as medical advice or substitute for consultation with a healthcare professional. If you or someone you know is experiencing depression or thoughts of suicide, please seek immediate treatment and/or call the National Suicide Prevention Lifeline by dialing 988 or the full number at 1-800-273-8255. Please note the views of the participants discussed on this podcast may not be representative of the views of other providers or individuals living with MDD.

This podcast series was sponsored by Sage Therapeutics, Inc. and Biogen Inc.

The Sage and Biogen names and logos are registered trademarks of their respective owners.
MRC-MDD-00446 …

Changing the Conversation About Mental Health: Patient & Provider Perspectives is a series of conversations that explores the need to openly and honestly discuss mental health topics to help bridge the communications gap that can exist between health care providers and people with mental health disorders. Throughout this podcast, a clinician and a person with MDD engage in a conversation about a different aspect of MDD – from the journey to diagnosis to the impact of MDD.

The information in this podcast is not intended to serve as medical advice or substitute for consultation with a healthcare professional. If you or someone you know is experiencing depression or thoughts of suicide, please seek immediate treatment and/or call the National Suicide Prevention Lifeline by dialing 988 or the full number at 1-800-273-8255. Please note the views of the participants discussed on this podcast may not be representative of the views of other providers or individuals living with MDD.

This podcast series was sponsored by Sage Therapeutics, Inc. and Biogen Inc.

The Sage and Biogen names and logos are registered trademarks of their respective owners.
MRC-MDD-00447 …